Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Mit der Einführung neuer Alzheimer-Therapien wie den Anti-Amyloid-Antikörpern Lecanemab und Donanemab rückt ein bislang wenig bekanntes, aber hochaktuelles Phänomen in den Fokus: ARIA – Amyloid-related Imaging Abnormalities. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
28/100
Neue Alzheimer-Therapien mit Anti-Amyloid-Antikörpern wie Lecanemab oder Donanemab eröffnen Betroffenen neue Chancen – stellen die Radiologie jedoch vor besondere Herausforderungen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is no longer viewed only as a clinical syndrome of memory impairment but as a biological disease continuum driven by interacting amyloid-β, tau, glial, vascular, metabolic, and synaptic mechanisms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is a pathological worsening process of neurodegenerative disease characterised by impaired thinking, memory and behavioural problems, which have a considerable health impact worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Study 1 was designed for 8 weeks with weekly 3D6.IgG2a injections, but was aborted after the first injection when 7/10 mice died within 36 hours. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Immunotherapy is rapidly becoming one of the most promising directions in the modern approach to cancer treatment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by a decline in cognitive abilities and memory impairment, representing the most common form of dementia worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parameters such as clinical status, GCA scale, MTA scale, Fazekas scale, strategic infarction, Koedam score, stroke, hypertension, diabetes mellitus, dyslipidemia, and cardiovascular disease do not have significant correlations with MoCA-INA scores. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The proposed approach achieves 97.9% AD Classification Index (ADCI) for the Kaggle dataset and 97.9% ADCI for the MIRIAD dataset. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer’s disease (AD) is a progressive neurological condition that leads to dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
28/100
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early detection of Alzheimer's disease is crucial for effective treatment, and the use of brain MRI images has become a common method for diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a progressive neurodegenerative disorder that significantly impacts memory, cognition, and daily functioning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease acts as a degenerative brain trauma that results in poor memory, alongside impairing mental functioning. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results may contribute to refining current diagnostic techniques, promoting earlier detection, and assisting in the development of advanced tools for accurate brain tumor diagnosis and treatment planning. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
28/100
Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Symptoms of mania have been given inadequate attention as a source of agitated behavior in the dementia patient. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
28/100
While this process allows machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Dr. Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method in the diagnosis of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, AI has substantial potential to support more precise, person-centred care for older adults, but realising this promise will require multimorbidity-aware, transparent models, robust evaluation in diverse geriatric populations and governance frameworks that ensure fairness, privacy and meaningful human oversight. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review analyzes current data on the epidemiology, pathogenesis, clinical features, and approaches to the treatment of cognitive impairments in diabetes mellitus (DM). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease is the most common type of dementia, characterized by a progressive decline in cognitive function, particularly memory and impacting daily life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →